Results 31 to 40 of about 1,824,517 (243)

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann   +8 more
wiley   +1 more source

Clinical analysis of 11 cases of nocardiosis

open access: yesOpen Medicine, 2021
Nocardiosis is a rare, life-threatening, opportunistic, and suppurative infection. Its clinical manifestation lacks specificity, which makes early diagnosis difficult.
Li Yiqing   +7 more
doaj   +1 more source

Clinical and laboratory profile in confirmed vs. suspected septic arthritis patients and its relevance in decision making: A comparative cross-sectional study

open access: yesChinese Journal of Traumatology, 2021
Purpose: There were 10%–30% of patients with adult-onset septic arthritis (SA) exhibiting sterile synovial fluid (SF), and the uncertainty in the determining diagnosis of these patients posed a challenge in management.
Sandeep K. Nema   +3 more
doaj   +1 more source

Abatacept for Prophylaxis of Acute and Chronic Graft‐Versus‐Host‐Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta‐Analysis of Cohort Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Graft‐versus‐host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T‐cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases

open access: yesHuman Vaccines & Immunotherapeutics, 2019
Streptococcus pneumoniae causes pneumonia, meningitis, otitis media, and bacteremia. The mortality and morbidity of invasive pneumococcal disease are high among adults aged >65 years or those with underlying chronic or immunosuppressive conditions.
Koji Kuronuma, Hiroki Takahashi
doaj   +1 more source

Phaeohyphomycosis in renal transplantation: report of two cases [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2016
Phaeohyphomycosis is an infection caused by a filamentous fungus that contains pigment melanin in its cell wall. We report two cases caused by Exophiala sp.
Walmar Roncalli Pereira de Oliveira   +5 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

open access: yesFEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward   +2 more
wiley   +1 more source

Squamous cell carcinoma developing De Novo in an untreated, nonsun-exposed psoriatic plaque

open access: yesIndian Journal of Medical and Paediatric Oncology, 2019
Psoriasis is a chronic inflammatory dermatosis, which causes hyperproliferation of skin. Patients afflicted with psoriasis are also at a risk of developing nonmelanoma skin cancers, with the risk of such a possibility being attributed to the ...
Sidharth Tandon   +3 more
doaj   +1 more source

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

open access: yesJEADV Clinical Practice, 2022
Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse.
Linde deWijs   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy